Search results (251)
« Back to NewsIntroducing OxVax
13 June 2021
OXvax Ltd. is a spin-out company from the University of Oxford focused on developing an advanced next-generation dendritic cell vaccine platform for treating solid tumour cancers.
Alchemab Therapeutics wins Best Start-up Biotech Company at the OBN Awards 2020
10 June 2021
Alchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.
BioEscalator Pitch Battle 2021
8 June 2021
PepGen wins the BioEscalator Pitch Battle 2021 with an excellent pitch on how the company is harnessing the power of its Enhanced Delivery Peptide technology to solve the drug-delivery challenge and realize the clinical potential of oligonucleotide therapies to transform the lives of people living with neuromuscular diseases.
Introducing Exogene
1 June 2021
Exogene is a biotechnology company discovering novel T-cell receptor (TCR)-based cell therapies to treat advanced solid tumours.
MoA Technology graduates from The BioEscalator
31 May 2021
MoA Technology is in the process of moving to the Bellhouse Building at the Oxford Science Park to continue its mission to provide farmers with a diverse choice of innovative technologies for weed control.
HRH The Earl of Wessex visits Oxfordshire virtually
17 May 2021
HRH The Earl of Wessex speaks with Oxfordshire entrepreneurs, including Atherton Mutombwera, CEO of Hutano Diagnostics.
Alchemab moves on from the BioEscalator
29 April 2021
Alchemab Therapeutics, the antibody therapeutic start-up backed by SV Health Investors, has graduated from the BioEscalator after 18 months in the Innovation Labs.
MoA Technology secures further funding
26 April 2021
MoA Technology, a spin-out company from Oxford University’s Department of Plant Sciences, has secured an additional £5M funding for its series A round to support the expansion and acceleration of its discovery programme.
Alchemab raises £60M series A funding
16 April 2021
The biotech company, which joined the BioEscalator Innovation Lab as a new start-up in December 2019, secures Series A funding to advance its novel platform for identifying disease-modifying antibody therapeutics.
Introducing Accunea
10 March 2021
Accunea is pioneering the next generation of continuous, real-time organ function monitoring to ensure every transplant counts.
MediMabBio raises ₩18B (£11.4M) series A funding
26 February 2021
BioEscalator biotech, MediMab Biotherapeutics, secures Series A funding to advance two immuno-oncology candidate therapeutics in pre-clinical studies.
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies
12 January 2021
The partnership deal, worth over €876M, will enable Enara Bio to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.
Theolytics Raises £5M ($6.8M) Series A round Co-led by Epidarex Capital and Taiho Ventures
6 January 2021
Theolytics raises £5M ($6.8M) Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies.
Enara Bio moves to The Oxford Science Park
9 December 2020
Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies.
PepGen raises $45M Series A
9 December 2020
RA Capital Management leads $45M Series A financing for PepGen’s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases. PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round.
Base Genomics acquired by Exact Sciences for $410M
28 October 2020
We are excited to announce that one of our resident companies, Base Genomics, has been acquired by Exact Sciences for $410 million. The acquisition will undoubtedly further propel Base Genomics' groundbreaking technology alongside Exact Sciences' existing expertise, ultimately enhancing cancer diagnostics.
Alchemab Announced as Finalists for OBN Awards 2020
5 October 2020
Novel therapeutics company, Alchemab Therapeutics, has been shortlisted in the Best Start-Up category of the 12th Annual OBN Awards.
UK-based Alchemab partners with Amii to accelerate the development of novel therapeutics to cure disease
30 September 2020
Alchemab announced a strategic partnership with the Alberta Machine Intelligence Institute (Amii) to accelerate its adoption of artificial intelligence.
Oxford Seed Fund announces 2020 investments in Hutano Diagnostics
14 September 2020
The Oxford Seed Fund (OSF) is a student-led seed fund and an initiative of Said Business School’s Entrepreneurship Centre. Of the hundreds of start-up applications the team reviewed, OSF is excited to announce one of this year’s start-up investments is Hutano Diagnostics.